The Cox Proportional Hazards Approach in Survival Analysis of an Ovarian Cancer Dataset with Stratification and an Extended Model
DOI:
https://doi.org/10.54065/likelihood.1040Keywords:
Survival Analysis, Cox Proportional Hazards Model, Stratified Cox Model, Variable Interaction, Ovarian Cancer Dataset, Mortality RiskAbstract
This analysis uses the Ovarian dataset available on the R Pubs platform to evaluate the factors influencing the risk of an event occurring. This dataset is one of the most commonly used survival datasets for analyzing treatment effectiveness or risk factors in medical research. The aim of this analysis is to evaluate the Cox Proportional Hazards model in analyzing the factors influencing the risk of an event occurring, while accounting for interactions between variables. The two model approaches tested are the Stratified Cox and Extended Cox models, both with and without interactions. The evaluation was conducted using four primary methods: the Concordance Index, Dynamic-AUC, Brier Score, and Integrated Square Error. The likelihood ratio test results indicate that the inclusion of interactions does not significantly improve model fit, as evidenced by p-values > 0.05 for both model approaches. Therefore, the Stratified Cox model without interactions was selected as the best model. This model is considered simpler yet still capable of providing an accurate interpretation of the relationship between the studied variables and the risk of an event. The selection of this model is expected to make a significant contribution to the development of survival analysis, particularly in applications involving complex data with stratification factors. The analysis results indicate that patient age is significantly associated with the risk of death; each additional year of age increases the risk of death by approximately 2.4%. Treatment type and the presence of residual disease are not significantly associated with the risk of death; however, the analysis results show that patients receiving experimental treatment have a 28.4% lower risk of death, and patients with residual disease have a 38.9% higher risk of death compared to patients without residual disease.
References
Bradburn, M. J., Clark, T. G., Love, S. B., & Altman, D. G. (2003). Survival analysis part II: multivariate data analysis–an introduction to concepts and methods. British journal of cancer, 89(3), 431-436.
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 68(6), 394-424. https://doi.org/10.3322/caac.21492
Coburn, S. B., Bray, F., Sherman, M. E., & Trabert, B. (2017). International patterns and trends in ovarian cancer incidence, overall and by histologic subtype. International journal of cancer, 140(11), 2451-2460. https://doi.org/10.1002/ijc.30676
D. W. Hosmer, S. Lemeshow och S. (2011), Applied Survival Analysis: Regression Modeling of Time-to-Event Data, NJ: John Wiley & Sons.
Du Bois, A., Reuss, A., Pujade?Lauraine, E., Harter, P., Ray?Coquard, I., & Pfisterer, J. (2009). Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO?OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer, 115(6), 1234-1244. https://doi.org/10.1002/cncr.24149
Fleming, T. R., & Lin, D. Y. (2000). Survival analysis in clinical trials: past developments and future directions. Biometrics, 56(4), 971-983.
Harrington, D. P., & Fleming, T. R. (1982). A class of rank test procedures for censored survival data. Biometrika, 69(3), 553-566.. https://doi.org/10.1093/biomet/69.3.553
Kaplan, E. L., & Meier, P. (1958). Nonparametric estimation from incomplete observations. Journal of the American statistical association, 53(282), 457-481. https://doi.org/10.1080/01621459.1958.10501452
Kartsonaki, C. (2016). ”Survival analysis,” Diagnostics, 6(1), 11
M. Mondal och L. C. P, ”, "A framework for survival analysis based on modeling of cumulative hazard function using a hybrid neural network,” Expert Systems with Applications, vol. 85, pp. 106-118, 2017.
Momenimovahed, Z., Tiznobaik, A., Taheri, S., & Salehiniya, H. (2019). Ovarian cancer in the world: epidemiology and risk factors. International journal of women's health, 287-299. https://doi.org/10.2147/IJWH.S197604
Mukaromah, M. (2020). Analisis Survival pada Data Kanker Ovarium. MATHunesa: Jurnal Ilmiah Matematika, 8(2), 130-134.
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982). Toxicity and response criteria of the Eastern Cooperative Oncology Group. American journal of clinical oncology, 5(6), 649-656.
Peto, R., Pike, M., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., ... & Smith, P. G. (1977). Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. British journal of cancer, 35(1), 1-39.
Pocock, S. J., Clayton, T. C., & Altman, D. G. (2002). Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. The Lancet, 359(9318), 1686-1689.
S. P. Wright, C. B. Langman och C. A. Mitchell (2019). ” Proportional hazards assumption in survival analysis: Testing and consequences,” Journal of Applied Statistics. 46(5). 834–845,.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Luqyana Zakiya Almaz, Rizki Adisetya Tahwin, Ifayanti Rohmatul H, Anisya Safira, Sri Sulastri

This work is licensed under a Creative Commons Attribution 4.0 International License.





